(Q34579405)

3 August 2017

1 reference

title

Arsenic trioxide: a new immunomodulatory agent in the management of multiple myeloma (English)

1 reference

3 August 2017

1 reference

Hussein MA

1

1 reference

3 August 2017

1 January 2001

1 reference

3 August 2017

1 reference

3 August 2017

18

1 reference

3 August 2017

239-242

1 reference

3 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1385/mo:18:4:239

3 August 2017

0 references

cites work

Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma

1 reference

12 December 2020

Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells

1 reference

12 December 2020

Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system.

1 reference

12 December 2020

Arsenicals in hematologic cancers

1 reference

12 December 2020

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

1 reference

12 December 2020

Multiple myeloma: increasing evidence for a multistep transformation process

1 reference

12 December 2020

Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients

1 reference

12 December 2020

The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms

1 reference

12 December 2020

Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis

1 reference

12 December 2020

Identifiers

DOI

10.1385/MO:18:4:239

1 reference

PubMed ID

11918450

Dimensions Publication ID

3 August 2017

0 references

1 reference

PubMed ID

11918450